Search Orphan Drug Designations and Approvals
-
Generic Name: | Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase |
---|---|
Date Designated: | 03/03/2011 |
Orphan Designation: | Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-